Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
482 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02478502 | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | terminated | Phase 2 | 14 | University Hospital, AkershusOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | withdrawn | Phase 2 | 0 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06169072 | Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients(MagSnow2) | recruiting | Phase 2 | 220 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT00494234 | Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer(ICEBERG 1) | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 8 | Jan 19, 2024 | clinicaltrials |
| NCT03674112 | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer(PHranceSCa) | completed | Phase 2 | 160 | Hoffmann-La RocheINDUSTRY | 17 | Jan 2, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye(PEMDAC) | completed | Phase 2 | 29 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 8, 2023 | clinicaltrials |
| NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | recruiting | Phase 2 | 200 | Karolinska University HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05289076 | Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model(CRLM-Z) | unknown | Phase 1 / Phase 2 | 40 | University Hospital, LinkoepingOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT00818623 | Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | completed | Phase 2 | 172 | Ferring PharmaceuticalsINDUSTRY | 7 | Nov 30, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab(OpACIN-neo) | unknown | Phase 2 | 186 | The Netherlands Cancer InstituteOTHER | 4 | Nov 15, 2023 | clinicaltrials |
| NCT04558931 | Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | recruiting | Phase 2 | 62 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT03155100 | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines(KEd) | completed | Phase 2 | 15 | Raija SilvennoinenOTHER | 2 | Sep 26, 2023 | clinicaltrials |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer(RELEASE) | terminated | Phase 2 | 41 | PCI Biotech ASINDUSTRY | 14 | Sep 11, 2023 | clinicaltrials |
| NCT05082675 | Stem Cell Translpantation in Multiple Myeloma | completed | Phase 2 | 357 | European Society for Blood and Marrow TransplantationNETWORK | 11 | Sep 11, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | completed | Phase 2 | 206 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 21, 2023 | clinicaltrials |
| NCT05961761 | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients(PROPANE) | recruiting | Phase 2 | 80 | Niels JunkerOTHER | 3 | Jul 27, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT02365441 | A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)(ALT GIST) | unknown | Phase 2 | 78 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Jul 7, 2023 | clinicaltrials |
| NCT00093041 | Zalutumumab in Head and Neck Cancer | completed | Phase 1 / Phase 2 | 28 | GenmabINDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT01307605 | Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | terminated | Phase 2 | 154 | Swiss Cancer InstituteOTHER | 3 | Jun 27, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT00071084 | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. | completed | Phase 2 | 22 | GenmabINDUSTRY | 4 | Apr 28, 2023 | clinicaltrials |
| NCT02504346 | AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies(TREM) | unknown | Phase 2 | 200 | Oslo University HospitalOTHER | 5 | Mar 28, 2023 | clinicaltrials |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | completed | Phase 2 | 345 | PharmaMarINDUSTRY | 9 | Mar 2, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT02807454 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma(FUSIONMM-003) | terminated | Phase 2 | 37 | CelgeneINDUSTRY | 9 | Feb 21, 2023 | clinicaltrials |
| NCT02606461 | Selinexor in Advanced Liposarcoma(SEAL) | completed | Phase 2 / Phase 3 | 342 | Karyopharm Therapeutics IncINDUSTRY | 10 | Jan 23, 2023 | clinicaltrials |
| NCT05553808 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 | completed | Phase 2 | 105 | GlaxoSmithKlineINDUSTRY | 12 | Jan 19, 2023 | clinicaltrials |
| NCT01838369 | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | terminated | Phase 2 | 4 | BioInvent International ABINDUSTRY | 1 | Jan 11, 2023 | clinicaltrials |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | completed | Phase 2 | 122 | Millennium Pharmaceuticals, Inc.INDUSTRY | 18 | Dec 20, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT01597414 | Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 | completed | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Nov 17, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT02387996 | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | completed | Phase 2 | 270 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 1, 2022 | clinicaltrials |
| NCT03697707 | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia(ADVANCE-II) | unknown | Phase 2 | 20 | MendusINDUSTRY | 5 | Oct 10, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | completed | Phase 2 | 535 | AmgenINDUSTRY | 12 | Sep 22, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02432846 | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)(MERECA) | completed | Phase 2 | 88 | MendusINDUSTRY | 9 | Aug 22, 2022 | clinicaltrials |
| NCT01064375 | Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer(El-porCEA) | completed | Phase 1 / Phase 2 | 16 | Maria LiljeforsOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies(CheckMate 908) | completed | Phase 2 | 166 | Bristol-Myers SquibbINDUSTRY | 15 | Aug 9, 2022 | clinicaltrials |
| NCT02678299 | Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study | unknown | Phase 1 / Phase 2 | 60 | University of AarhusOTHER | 5 | Aug 4, 2022 | clinicaltrials |
| NCT03226301 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | unknown | Phase 2 | 230 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 6 | Aug 2, 2022 | clinicaltrials |
| NCT03101475 | Synergism of Immunomodulation and Tumor Ablation(ILOC) | completed | Phase 2 | 22 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 31, 2022 | clinicaltrials |
| NCT05133674 | Therapeutic Dose Monitoring (TDM) of Tamoxifen | unknown | Phase 2 | 40 | Karolinska University HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT01898312 | BRCA1/2 and Effect of Mifepristone on the Breast | completed | Phase 2 | 45 | Karolinska InstitutetOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02038946 | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | completed | Phase 2 | 116 | Bristol-Myers SquibbINDUSTRY | 12 | Jan 4, 2022 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials